Evidence map›Paper›PMID 29212628›Full record

ArticleJMIR mHealth and uHealth2017

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.

Amanda Pereira-Salgado, Jennifer A Westwood, Lahiru Russell, Anna Ugalde, Bronwen Ortlepp, John F Seymour, Phyllis Butow, Lawrence Cavedon, Kevin Ong, Sanchia Aranda and 4 more

Open access · goldAbstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Feasibility and preliminary effects of mhealth supportive care interventions in adults with myeloid neoplasms: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. A smart pill bottle and text messaging intervention for promoting medication adherence in patients with chronic myeloid leukemia: a pilot study of txt4 TKI.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  9. Article
  10. Article
  11. An investigation of the use of app technology to support clinical management of patients with chronic myeloid leukaemia (CML).Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023
    Article
  12. Article
  13. mHealth for Medication and Side Effect Monitoring: Patients' Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment.International Conference on Pervasive Computing Technologies for Healthcare : [proceedings]. International Conference on Pervasive Computing Technologies for Healthcare · 2023
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Amanda Pereira-SalgadoCentre for Nursing Research, Cabrini Institute, Malvern, Victoria, Australia.ORCID http://orcid.org/0000-0002-8353-8230
Jennifer A WestwoodDepartment of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2957-5767
Lahiru RussellSchool of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, Victoria, Australia.ORCID http://orcid.org/0000-0002-3806-0020
Anna UgaldeSchool of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, Victoria, Australia.ORCID http://orcid.org/0000-0002-2473-8435
Bronwen OrtleppDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.ORCID http://orcid.org/0000-0002-2985-7791
John F SeymourDepartment of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2188-6835
Phyllis ButowSchool of Psychology, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-3562-6954
Lawrence CavedonSchool of Science, RMIT University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-7464-857X
Kevin OngSchool of Science, RMIT University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-0034-8368
Sanchia ArandaDepartment of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-4170-9799
Sibilah BreenDepartment of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-9896-004X
Suzanne KirsaPharmacy Department, Monash Health, Clayton, Victoria, Australia.ORCID http://orcid.org/0000-0002-4029-3288
Andrew DunlevieDepartment of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-1476-201X
Penelope SchofieldDepartment of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-9495-9543
Peter MacCallum Cancer Centre · AUDeakin University · AURMIT University · AUThe University of Melbourne · AUCabrini Hospital · AUFlorey Institute of Neuroscience and Mental Health · AUMonash Health · AURoyal Adelaide Hospital · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOptimal dosing of oral tyrosine kinase inhibitor therapy is critical to treatment success and survival of patients with chronic myeloid leukemia (CML). Drug intolerance secondary to toxicities and nonadherence are significant factors in treatment failure.

objectiveThe objective of this study was to develop and pilot-test the clinical feasibility and acceptability of a mobile health system (REMIND) to increase oral drug adherence and patient symptom self-management among people with CML (chronic phase).

methodsA multifaceted intervention was iteratively developed using the intervention development framework by Schofield and Chambers, consisting of defining the patient problem and iteratively refining the intervention. The clinical feasibility and acceptability were examined via patient and intervention nurse interviews, which were audiotaped, transcribed, and deductively content analyzed.

resultsThe intervention comprised 2 synergistically operating elements: (1) daily medication reminders and routine assessment of side effects with evidence-based self-care advice delivered in real time and (2) question prompt list (QPL) questions and routinely collected individual patient adherence and side effect profile data used to shape nurses' consultations, which employed motivational interviewing to support adoption of self-management behaviors. A total of 4 consultations and daily alerts and advice were delivered over 10 weeks. In total, 58% (10/17) of patients and 2 nurses participated in the pilot study. Patients reported several benefits of the intervention: help in establishing medication routines, resolution of symptom uncertainty, increased awareness of self-care, and informed decision making. Nurses also endorsed the intervention: it assisted in establishing pill-taking routines and patients developing effective solutions to adherence challenges.

conclusionsThe REMIND system with nurse support was usable and acceptable to both patients and nurses. It has the potential to improve adherence and side-effect management and should be further evaluated.

Indexed as

Internetmedication adherencemobile phoneneoplasms

Identifiers

PMID29212628
PMCPMC5738545
OpenAlexW2773286788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.